# NYBC Ventures

> NYBC Ventures is a VC fund in Boston backing Biotechnology, Health Care and Therapeutics. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 19
- Last investment: Jun 2026
- Lead investor: 37%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nybc-ventures
- Website: https://www.nybc.org

NYBC Ventures is a VC fund in Boston focused on Biotechnology and Health Care. New York Blood Center created NYBC Ventures to accelerate innovation in blood-related fields and cellular therapies and technology. The fund was established by New York Blood Center with a $50 million investment and a mission to improve patients' lives by advancing therapeutics, enabling platforms and technologies, and driving collaborationsto expand NYBC's impact.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 42% |
| Health Care | 6 | 32% |
| Therapeutics | 5 | 26% |
| Medical | 3 | 16% |
| Life Science | 3 | 16% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 32% |
| Funding Round | 5 | 26% |
| Series B | 3 | 16% |
| Series A | 2 | 11% |
| Series C | 1 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 14 | 74% |
| United Kingdom | 1 | 5% |
| The Netherlands | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M | Series B | Jun 08, 2026 |  |
| Vitestro | Vitestro transform patient care with autonomous blood drawing technology. | $70M | Series B | Mar 10, 2026 |  |
| Cellular Origins | Cellular Origins is an automation manufacturing company that provides cell and gene therapies. | $40M | Series A | Dec 09, 2025 |  |
| Star Therapeutics | Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $125M | Series D | Sep 30, 2025 |  |
| Akadeum Life Sciences | Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other relatedareas.Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States. | $20M |  | Jun 03, 2025 |  |
| AvenCell | Based on our deep science and focused on patients in need. | $112M | Series B | Oct 22, 2024 |  |
| Vitestro | Vitestro transform patient care with autonomous blood drawing technology. | $21.3M | Series A | Apr 30, 2024 |  |
| Functional Fluidics | Functional Fluidics specializes in the standardization of clinical blood function assays to assess individual patient response. Functional Fluidics is setting the standard for the assessment of red blood cell health. It was founded in 2014 and headquartered in Detroit, Michigan. |  |  | Dec 07, 2023 |  |
| Vittoria Biotherapeutics | Vittoria Biotherapeutics develops gene-edited cell therapies.  they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings. | $15M |  | Nov 13, 2023 |  |
| Aronora | Aronora is a translational biotechnology company (aronorabio.com) engaged in the early-stage commercial development of proprietary biologic therapeutics, including recombinant monolconal antibodies and enzymes. |  |  | Oct 12, 2023 |  |

10 of 19 investments shown.

## Co-investors
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 3 deals together
- [Sonder Capital](https://shizune.co/investors/profile/sonder-capital) — VC Fund, 3 deals together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 2 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 2 deals together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does NYBC Ventures invest in?

NYBC Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Funding Round stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did NYBC Ventures last invest?

The most recent investment recorded for NYBC Ventures closed in Jun 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co